Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Non-cash Items (2018 - 2025)

Historic Non-cash Items for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to $7.2 million.

  • Cue Biopharma's Non-cash Items rose 3794.04% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 3794.04%. This contributed to the annual value of $5.1 million for FY2024, which is 1196.62% up from last year.
  • Latest data reveals that Cue Biopharma reported Non-cash Items of $7.2 million as of Q3 2025, which was up 3794.04% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Non-cash Items ranged from a high of $7.2 million in Q3 2025 and a low of $3.1 million during Q1 2021
  • In the last 5 years, Cue Biopharma's Non-cash Items had a median value of $4.4 million in 2022 and averaged $4.6 million.
  • In the last 5 years, Cue Biopharma's Non-cash Items grew by 17.89% in 2023 and then surged by 3794.04% in 2025.
  • Over the past 5 years, Cue Biopharma's Non-cash Items (Quarter) stood at $3.6 million in 2021, then grew by 23.57% to $4.4 million in 2022, then increased by 4.53% to $4.6 million in 2023, then rose by 11.97% to $5.1 million in 2024, then soared by 40.44% to $7.2 million in 2025.
  • Its Non-cash Items was $7.2 million in Q3 2025, compared to $6.3 million in Q2 2025 and $6.0 million in Q1 2025.